Drug Search Results
More Filters [+]

Lucanthone

Alternative Names: lucanthone
Latest Update: 2024-03-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Spectrum
Company Location: HENDERSON NV 89052
Company CEO: Thomas J. Riga
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lucanthone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Brain Cancer|Glioblastoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IRB00037529

P2

Withdrawn

Brain Cancer|Non-Small-Cell Lung Cancer

2017-11-29

SPI-LUC-11-01

P2

Terminated

Glioblastoma

2013-04-15

42%

Recent News Events